Journal
EUROPEAN JOURNAL OF CANCER
Volume 44, Issue 15, Pages 2162-2168Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2008.06.006
Keywords
ZK 304709; Phase I; Cell cycle arrest; Apoptosis induction; Angiogenesis inhibitor
Categories
Funding
- Bayer Pharma
Ask authors/readers for more resources
Purpose: The primary objectives of this study were to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ZK 304709, a novel multi-targeted growth inhibitor (MTGI (TM)), in man. Secondary end-points included safety evaluation, tolerability, pharmacokinetic profiling and assessment of response using standard and novel surrogate pharmacodynamic end-points. Materials and methods: Patients (n = 40) with advanced solid malignancies were treated with ZK 304709, administered orally once daily for 7 d with 14 d recovery. Doses were escalated in sequential cohorts of three patients with expansion to 6-7 patients should a dose-limiting toxicity occur. Results: ZK 304709 was safely administered up to 360 mg. However, above 90 mg blood concentrations increased only slightly. As this dose was not deemed likely to result in meaningful pharmacologic or clinical activity, the trial was stopped before the MTD was ascertained. it was therefore not possible to make a reliable assessment of efficacy or pharmacodynamic end-points. Conclusions: Due to the lack of further increment in blood concentrations above a dose of 90 mg, which was felt from previous animal studies to be unlikely to result in meaningful pharmacologic or clinical activity, this study was stopped early. (c) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available